Anticancer efficacy with cisplatin delivery systems

Akio Sugitachi, Yusuke Kimura, Tetsuya Itabashi, Miyuki Ikeda, Kazushige Ishida, Hironobu Noda, Teppei Matsuo, Satoshi Nishizuka, Koki Otsuka, Keisuke Koeda, Ayako Sato, Tomoki Takahashi, Go Wakabayashi

Research output: Contribution to journalArticlepeer-review


The authors devised two different types of cisplatin (CDDP) delivery systems; namely, System A and System B. The anticancer efficacy with each system was examined using cancer-bearing animals. Seventy-percent deacetylated chitin (DAC-70) was used as the drug carrier in the system. Cancer-bearing animals were prepared by intra-peritoneally (ip) inoculating the MM-46 cancer cells to C3H mice. Each novel system was also ip injected to the cancer-bearing mouse, and then survival time of each animal was recorded to evaluate the anti- cancer efficacy of the system. Both Systems A and B were viscoelastic sol at 25°C and slowly changed to gel at 37°C. Four-week survival rate of each animal treated with the System was as follows: System A 6/10 (60%), System B 10/11 (90.9%), conventional CDDP alone 3/9 (33.3%) and non-treated 0/7 (0%). No signs of recurrence of ascites were encountered in the long-term survived animals treated with System A and B. Our newly devised systems provided a favorable antitumor efficacy in vivo. Now, we will carry out further studies by making a clinically applicable novel conjugated system, DAC-70 and CDDP.

Original languageEnglish
Pages (from-to)2274-2276
Number of pages3
JournalJapanese Journal of Cancer and Chemotherapy
Issue number12
Publication statusPublished - 11-2010
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • General Medicine


Dive into the research topics of 'Anticancer efficacy with cisplatin delivery systems'. Together they form a unique fingerprint.

Cite this